Issue link: https://www.e-digitaleditions.com/i/1218534
8 March 2020 Tablets & Capsules working in the pharmaceutical and related industries, specifically regula- tory affairs, quality control, and qual- ity assurance. UK medicines must comply with EU law by end of 2020 AMSTERDAM, Netherlands— The European Medicines Agency (EMA) has announced that, following the UK's January 31 departure from the European Union (EU), pharma- ceutical companies will have a tran- sitional period through December 2020 during which EU pharmaceuti- cal law will continue to be applicable to the UK. This allows UK pharma- ceutical companies to remain in the EU market until the end of the year as they make the necessary changes to comply with EU law. Additionally, since the UK's official departure from the EU, no UK representatives can participate in meetings of EMA scien- tific committees, working parties, or the agency's management board. stages of drug development. The policies focus on the challenges as well as the potential opportunities of machine learning in drug discovery, preclinical research, and clinical trials. The policy options discussed include research, data access, standardiza- tion, human capital, regulatory cer- tainty, and status quo. To read the full report, visit gao.gov. USP updates dictionary of US and international drug names ROCKVILLE, MD—USP has published an updated version of the Dictionary of United States Adopted Names (USAN) and International Drug Names. The dictionary is available exclusively via a one-year online subscription and contains the updated USAN, nonpro- prietary and brand names, chemical structure graphics, CAS numbers, and official pronunciations. The dictio- nary is used by libraries, academic research centers, and healthcare pro- fessionals and also serves as a refer- ence for scientists and professionals FDA publishes guidances on drug interaction studies S I LV E R S P R I N G , M D — T h e FDA published two final guid- ances for industry on the clinical and in vitro drug interaction studies regarding cytochrome P450 enzyme and transporter-mediated drug inter- actions to assist drug developers in evaluating drug-drug interaction (DDI) potential during drug devel- opment and describe a systematic, risk-based approach for the assess- ment of DDIs. The information pro- vided by drug interaction studies can inform clinical risk management strategies for patients taking more than one medication. GAO supports machine learning in drug development WA S H I N G T O N , D C — T h e Government Accountability Office (GAO), an independent, nonparti- san agency that works for Congress, presented six policy options for the use of machine learning in the early EXPERIENCE THE DIFFERENCE THE ELIZABETH DIFFERENCE. Compression Tooling | Tablet Presses | Turrets | Replacement Parts| Field Services & Training Blister Packaging Tooling & Feeders | Tablet Press & Turret Repairs We understand that your products are trusted by consumers each and every day. Consistent quality of your solid dose products is expected and non-negotiable. Your products depend upon the integrity of your equipment and tooling. For over 65 years, Elizabeth Companies have put a personal guarantee on customer satisfaction and takes pride in delivering innovative solutions. We promise our customers an unequaled level of customer service, trust, product performance, and prompt & courteous communication. ELIZ.COM | 412-751-3000 @ELIZCOMPANIES